According to Zacks, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium. “
Other equities research analysts also recently issued research reports about the company. Credit Suisse Group AG reaffirmed a hold rating and set a $48.00 target price on shares of Galapagos NV in a report on Friday, June 17th. Janney Montgomery Scott assumed coverage on Galapagos NV in a report on Tuesday, August 30th. They set a buy rating and a $64.00 target price for the company. Three investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of €65.20 ($72.44).
Galapagos NV (NASDAQ:GLPG) opened at 65.51 on Monday. Galapagos NV has a 12 month low of $37.03 and a 12 month high of $73.37. The stock’s market capitalization is $3.02 billion. The firm’s 50-day moving average is $59.62 and its 200-day moving average is $53.01.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fiera Capital Corp bought a new position in shares of Galapagos NV during the second quarter worth about $302,000. Citadel Advisors LLC bought a new position in shares of Galapagos NV during the second quarter worth about $347,000. A.R.T. Advisors LLC bought a new position in shares of Galapagos NV during the first quarter worth about $547,000. Landscape Capital Management L.L.C. increased its position in shares of Galapagos NV by 114.7% in the first quarter. Landscape Capital Management L.L.C. now owns 17,389 shares of the company’s stock worth $727,000 after buying an additional 9,288 shares during the last quarter. Finally, P.A.W. Capital Corp bought a new position in shares of Galapagos NV during the second quarter worth about $1,109,000. 21.21% of the stock is owned by institutional investors.
Galapagos NV Company Profile
Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.